Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.44 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.38 |
| ▸ | MMP14 | P50281 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178255 | 1.00 | BCL2A1 (0.45) | BCL2A1SLC6A2SLC6A4SLC6A3ABL1 | |
| SCHEMBL4938713 | 1.00 | BCL2A1 (0.45) | BCL2A1SLC6A2SLC6A4SLC6A3ABL1 | |
| SCHEMBL14311559 | 0.88 | ADAMTS5 (0.40) | BCL2A1SLC6A2SLC6A4WEE1ADAMTS5 | |
| SCHEMBL3465481 | 0.84 | ADAMTS5 (0.42) | WEE1ADAMTS5ADAMTS4 | |
| SCHEMBL3465038 | 0.84 | ADAMTS5 (0.42) | WEE1ADAMTS5ADAMTS4 | |
| SCHEMBL3465040 | 0.84 | ADAMTS5 (0.42) | WEE1ADAMTS5ADAMTS4 | |
| SCHEMBL3465474 | 0.84 | ADAMTS5 (0.42) | WEE1ADAMTS5ADAMTS4 | |
| SCHEMBL3465043 | 0.84 | ADAMTS5 (0.42) | WEE1ADAMTS5ADAMTS4 | |
| SCHEMBL23134696 | 0.83 | AR (0.52) | — | |
| SCHEMBL4596985 | 0.83 | AR (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176856-A1 | Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-07-24 | — | — | US | claimed |
| US-20080176856-A1 | Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2008-07-24 | — | — | US | disclosed |
| EP-1761512-A1 | NOVEL ALKYL SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123707-A1 | NOVEL ALKYL SUBSTITUTED PIPERAZINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176856-A1 | Novel Alkyl Substituted Piperidine Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | BCL2A1 4197/4885SLC6A2 2/4885SLC6A4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.